Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
MRI-Derived Lymph Nodes Morphological and Topological Structure (LNs-MTS) Model for Evaluating Immune Status and Prognosis in Rectal Cancer.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Yunxiao, Zhang Liwen, Cui Yanfen, Zhang Weiyuan, Hu Hanqing, Jiao Shuai, Ma Jian, Li Jiale, Xiang Jun, Li Jinna, Liu Haiyi, Yang Xiaotang, Tian Jie, Wang Xishan, Wang Guiyu, Guan Xu
Аннотация
Tumor-draining lymph nodes (LNs) immune status critically influences cancer progression and treatment response, yet reliable non-invasive assessment remains clinically unavailable. To address this critical gap, an MRI-derived LNs morphological and topological structure (LNs-MTS) model is developed to evaluate the immune status of LNs in rectal cancer (RC). Integrating multicenter imaging, transcriptomic, and immunohistochemical data from 1,156 stage I-II RC patients, enhanced immune activation in non-metastatic LNs sized ≥0.5 cm and located ≥5 cm from the primary tumor is discovered. Then two quantitative MRI-derived imaging features across 7,030 radiologically annotated LNs: total LNs volume (tLNV) and total LNs drainage distance (tLND) is developed, forming the basis of the LNs-MTS model risk subtypes: high-risk (HRS), moderate-risk (MRS), and low-risk (LRS). Patients in the LRS (characterized by large tLNV and distant tLND) show robust immune cell infiltration in the tumor microenvironment and excellent 5-year survival, whereas HRS (characterized by small tLNV and near tLND) show stromal dominance and poorer prognosis. Clinically, LNs-MTS offers a more precise and personalized risk assessment than current guideline-based risk stratification, potentially sparing stage II-LRS patients from unnecessary adjuvant treatment while identifying stage I-HRS individuals for more aggressive treatment, providing valuable insights for personalized treatment strategies in RC management.